combination therapies, with some early results showing promise and potential for new therapy plans. Systemic therapy for hepatocellular carcinoma is complicated by the significant heterogeneity of the disease and its propensity for developing drug resistance. Therefore, it is essential to choose a better,...
Hepatocellular carcinoma (HCC) is one of the most common malignant tumours worldwide. The major etiologies and risk factors for HCC development are well defined and some of the multiple steps involved in hepatocarcinogenesis have been elucidated in recent years. Despite these scientific advances and ...
Avelumab is an anti-PD-L1 drug approved by the FDA for urothelial tumors [65] and renal cell carcinoma [66]. As a potent TKI targeting VEGFR1/2/3, axitinib has been approved for the second-line treatment for advanced renal cell carcinoma patients [67]. In 2019, an ASCO-reported phase...
Treatment of hepatocellular carcinoma 来自 Semantic Scholar 喜欢 0 阅读量: 39 作者: HE Blum 摘要: Hepatocellular carcinoma (HCC) is one of the most common malignant tumours worldwide. The major etiologies and risk factors for HCC development are well defined and some of the multiple steps ...
1 Hepatocellular carcinoma (HCC) is the most common pathological type of PMC, and accounts for more than 80% of cases.2 However, in clinical practice, the outcomes of HCC treatment are unsatisfactory. Since the early stages of HCC do not necessarily manifest typical symptoms, a considerable ...
篇名 Locoregional treatment for hepatocellular carcinoma:The best is yet to come 来源期刊 世界放射学杂志:英文版(电子版) 学科 医学 关键词 HEPATOCELLULAR carcinoma High INTENSITY focussed u 年,卷(期) 2015,(10) 所属期刊栏目 研究方向 页码范围 306-318 页数 13页 分类号 R735.7 字数 语种 DOI ...
Treatment of hepatocellular carcinoma with chemoembolization and liver transplantation: , P. Moreno, C. Valls, C. Benasco, J. Virgili, J. Dominguez, C. Sancho, A. Rafecas, T. Casanovas, J. Fabregat, X. Xiol, J. Torras, E. Jaurrieta, C.S.U. Bellvitge, University of Barcelona, Spain...
Chronic hepatitis B virus (HBV) infection is the primary risk factor for the development of hepatocellular carcinoma worldwide. After decades of chronic he... CJ Liu,JH Kao - 《Journal of the Chinese Medical Association》 被引量: 232发表: 2007年 Relation of hemochromatosis with hepatocellular ca...
Hepatocellular carcinoma (HCC) is, in the large majority of cases, a secondary disease; cirrhosis as the result of long-standing chronic liver disease is the premalignant precursor condition. 1 Cirrhosis is a diffuse process, and thus the entire liver is at risk for the development of HCC. Fu...
Hepatocellular carcinoma(HCC) is the sixth most prevalent malignancy worldwide and is a rising cause of cancer related mortality. Risk factors for HCC are well documented and effective surveillance and early diagnosis allow for curative therapies. The majority of HCC appears to be caused by cirrhosis...